CN110878129B - 一种氨基葡萄糖肝素盐及其应用 - Google Patents
一种氨基葡萄糖肝素盐及其应用 Download PDFInfo
- Publication number
- CN110878129B CN110878129B CN201911242820.0A CN201911242820A CN110878129B CN 110878129 B CN110878129 B CN 110878129B CN 201911242820 A CN201911242820 A CN 201911242820A CN 110878129 B CN110878129 B CN 110878129B
- Authority
- CN
- China
- Prior art keywords
- glucosamine
- heparin
- salt
- heparin salt
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 title claims abstract description 69
- 229960002442 glucosamine Drugs 0.000 title claims abstract description 69
- -1 Glucosamine heparin salt Chemical class 0.000 title claims abstract description 55
- 229920000669 heparin Polymers 0.000 claims abstract description 47
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims abstract description 46
- 229960002897 heparin Drugs 0.000 claims abstract description 35
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 claims abstract description 25
- 239000003814 drug Substances 0.000 claims abstract description 13
- 238000005342 ion exchange Methods 0.000 claims abstract description 11
- 238000000502 dialysis Methods 0.000 claims abstract description 8
- 235000013376 functional food Nutrition 0.000 claims abstract description 5
- 150000003839 salts Chemical class 0.000 claims description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 10
- 150000002500 ions Chemical class 0.000 claims description 10
- 239000003146 anticoagulant agent Substances 0.000 claims description 9
- 150000002301 glucosamine derivatives Chemical class 0.000 claims description 9
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 8
- 238000006243 chemical reaction Methods 0.000 claims description 7
- 238000001694 spray drying Methods 0.000 claims description 7
- 238000002156 mixing Methods 0.000 claims description 6
- 229940127219 anticoagulant drug Drugs 0.000 claims description 5
- 239000012528 membrane Substances 0.000 claims description 5
- 239000000843 powder Substances 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 2
- 235000013305 food Nutrition 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 230000001376 precipitating effect Effects 0.000 claims 1
- CBOJBBMQJBVCMW-BTVCFUMJSA-N (2r,3r,4s,5r)-2-amino-3,4,5,6-tetrahydroxyhexanal;hydrochloride Chemical compound Cl.O=C[C@H](N)[C@@H](O)[C@H](O)[C@H](O)CO CBOJBBMQJBVCMW-BTVCFUMJSA-N 0.000 abstract description 13
- 229960001911 glucosamine hydrochloride Drugs 0.000 abstract description 13
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 abstract description 12
- 229960001008 heparin sodium Drugs 0.000 abstract description 11
- 229940079593 drug Drugs 0.000 abstract description 5
- 238000001556 precipitation Methods 0.000 abstract description 5
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 abstract description 4
- 230000000694 effects Effects 0.000 abstract description 4
- 229910019142 PO4 Inorganic materials 0.000 abstract description 3
- 150000001875 compounds Chemical class 0.000 abstract description 3
- 229960002849 glucosamine sulfate Drugs 0.000 abstract description 3
- 239000010452 phosphate Substances 0.000 abstract description 3
- 238000000855 fermentation Methods 0.000 abstract description 2
- 230000004151 fermentation Effects 0.000 abstract description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 abstract description 2
- 238000006116 polymerization reaction Methods 0.000 abstract description 2
- 230000010100 anticoagulation Effects 0.000 abstract 2
- 239000011259 mixed solution Substances 0.000 abstract 2
- 150000004676 glycans Chemical class 0.000 abstract 1
- 229920001282 polysaccharide Polymers 0.000 abstract 1
- 239000005017 polysaccharide Substances 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 description 15
- 239000001257 hydrogen Substances 0.000 description 15
- 239000000047 product Substances 0.000 description 11
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 10
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 8
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 8
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 8
- 229950006780 n-acetylglucosamine Drugs 0.000 description 8
- 150000001450 anions Chemical class 0.000 description 6
- 150000001768 cations Chemical class 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 108010094028 Prothrombin Proteins 0.000 description 5
- 102100027378 Prothrombin Human genes 0.000 description 5
- 108090000190 Thrombin Proteins 0.000 description 5
- 229940039716 prothrombin Drugs 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 238000001228 spectrum Methods 0.000 description 5
- 229960004072 thrombin Drugs 0.000 description 5
- PGOHTUIFYSHAQG-LJSDBVFPSA-N (2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]hexanoic acid Chemical compound CSCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O PGOHTUIFYSHAQG-LJSDBVFPSA-N 0.000 description 4
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 108010000499 Thromboplastin Proteins 0.000 description 4
- 102000002262 Thromboplastin Human genes 0.000 description 4
- AEMOLEFTQBMNLQ-WAXACMCWSA-N alpha-D-glucuronic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-WAXACMCWSA-N 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 238000005303 weighing Methods 0.000 description 4
- 230000002785 anti-thrombosis Effects 0.000 description 3
- 239000012043 crude product Substances 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 238000001631 haemodialysis Methods 0.000 description 3
- 230000000322 hemodialysis Effects 0.000 description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 3
- 239000012535 impurity Substances 0.000 description 3
- 210000004379 membrane Anatomy 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 210000002381 plasma Anatomy 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 229910001415 sodium ion Inorganic materials 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- MTDHILKWIRSIHB-UHFFFAOYSA-N (5-azaniumyl-3,4,6-trihydroxyoxan-2-yl)methyl sulfate Chemical compound NC1C(O)OC(COS(O)(=O)=O)C(O)C1O MTDHILKWIRSIHB-UHFFFAOYSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 229920002101 Chitin Polymers 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
- 230000002429 anti-coagulating effect Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000015271 coagulation Effects 0.000 description 2
- 238000005345 coagulation Methods 0.000 description 2
- 230000000593 degrading effect Effects 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 238000000909 electrodialysis Methods 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000003055 low molecular weight heparin Substances 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 229910021645 metal ion Inorganic materials 0.000 description 2
- 230000014508 negative regulation of coagulation Effects 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 239000012266 salt solution Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 206010062713 Haemorrhagic diathesis Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 102000055008 Matrilin Proteins Human genes 0.000 description 1
- 108010072582 Matrilin Proteins Proteins 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 208000001435 Thromboembolism Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 210000001188 articular cartilage Anatomy 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000005341 cation exchange Methods 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000005684 electric field Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 208000031169 hemorrhagic disease Diseases 0.000 description 1
- 229940095529 heparin calcium Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 229960001078 lithium Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229940127215 low-molecular weight heparin Drugs 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000002891 organic anions Chemical class 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000002390 rotary evaporation Methods 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 238000000967 suction filtration Methods 0.000 description 1
- MGXQNMLHMKAXJR-JSCKKFHOSA-N sulfuric acid;(2s,3s,4s,5r)-2,3,4,5-tetrahydroxy-6-oxohexanoic acid Chemical compound OS(O)(=O)=O.O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O MGXQNMLHMKAXJR-JSCKKFHOSA-N 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
- C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
- C08B37/0075—Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Polymers & Plastics (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Materials Engineering (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明涉及功能食品及医药行业,具体是一种氨基葡萄糖肝素盐及应用。氨基葡萄糖肝素盐结构式如式(1)所示,其中,平均聚合度n取值范围是5‑500。所述氨基葡萄糖肝素盐由氨基葡萄糖盐酸盐或硫酸盐或磷酸盐与肝素钠通过离子交换、或者混合溶液透析、或者混合溶液直接沉淀得到,其中,所用肝素分子量为天然提取、或经过发酵制备、或降解得到、或通过合成方法得到的符合肝素结构的所有多糖。本发明把肝素与氨基葡萄糖有机结合在一起,区别于现有的二者的复配产品,纯度更高,制备的氨基葡萄糖肝素盐具有较强的抗凝血作用,可用于但不限于抗凝血药物治疗或辅助保健功效的用途。氨基葡萄糖肝素盐可以广泛应用于功能食品及医药领域。
Description
技术领域
本发明涉及功能食品及医药行业,具体是一种氨基葡萄糖肝素盐及其应用。
背景技术
氨基葡萄糖类化合物是一类治疗骨关节炎的特异性药物,也是人体关节软骨基质中合成氨基多糖所必需的重要成分。目前,报道的氨基葡萄糖类化合物几乎都是以氨基葡萄糖无机酸盐的形式存在,主要包括其盐酸盐、硫酸盐以及含镁钙等金属元素的复合盐等。其中,氨基葡萄糖盐酸盐主要是通过甲壳素在盐酸以及高温条件下降解得到;氨基葡萄糖硫酸盐的制备,一种方法是甲壳素通过硫酸降解而得,一种方法是通过氨基葡萄糖盐酸盐的盐置换而得到。各种氨基葡萄糖复合盐的制备也是通过氨基葡萄糖盐酸盐的盐置换而得到。大部分无机盐,比如钠、镁、钾、钙等金属离子在人体中是不能大量摄入的,否则会引起体内电解质的变化,引发一系列问题。此外,关于氨基葡萄糖有机酸盐的制备研究较少。
肝素是一种抗凝剂,是由萄糖胺、L-艾杜糖醛苷、N-乙酰葡萄糖胺和D-葡萄糖醛酸硫酸酯交替连接而成的多聚体,在体内外都有抗凝血作用。临床上主要用于血栓栓塞性疾病、心肌梗死、心血管手术、心脏导管检查、体外循环、血液透析等。随着药理学及临床医学的进展,肝素的应用不断扩大。目前肝素是世界上最有效和临床用量最大的抗凝血药物,主要应用于心脑血管疾病和血液透析治疗,其中,其在血液透析治疗中是唯一有效的特效药物。肝素原料药的原料是肝素粗品,其提取主要源自健康生猪的小肠粘膜,由于含有大量杂质蛋白、杂质核酸、微生物等杂质,需经过物理和化学提取分离过程,定向获取天然结构基团完整的肝素,从而制成肝素原料药。低分子肝素是由普通肝素裂解而来。与普通肝素比较,其抗血栓能力较强而抗凝血能力较低,在其抗血栓能力形成时对凝血系统的影响较小。另外低分子肝素还具有分子量小、生物利用度高、体内半衰期长、出血倾向小等特点。
目前流行的产品是氨基葡萄糖盐酸盐、氨基葡萄糖硫酸盐、氨基葡萄糖磷酸盐的单品。肝素是一种用途广泛的临床药物,作为抗凝剂和抗血栓药在临床上使用已有60余年,但长期使用会导致出血和血小板减少等不良现象。相应的分子改良工作具有重要意义。
发明内容
本发明目的是提供一种区别于氨基葡萄糖盐酸盐以及传统肝素钠的新型化合物的一种氨基葡萄糖肝素盐及其制备方法和应用。
为实现上述目的,本发明采用技术方案为:
一种氨基葡萄糖肝素盐,氨基葡萄糖肝素盐结构式如式(1)所示,
所述氨基葡萄糖盐类与肝素盐于离子交换、透析、膜分离或沉淀方式,实现两种原料的离子交换反应以及纯化,即得式(1)所示氨基葡萄糖肝素盐;其中,氨基葡萄糖盐类与肝素盐的质量比为1:5-5:1。
所述氨基葡萄糖盐类为氨基葡萄糖的盐酸盐、硫酸盐或磷酸盐;所述肝素盐为通过天然提取、发酵制备、降解或化学合成方法得到;例如肝素钠、肝素锂、肝素钙、肝素钾、肝素锌等。
所述肝素盐与氨基葡萄糖盐类,混合或分别溶于水中,于透析袋中进行离子交换,氨基葡萄糖通过正离子(阳离子)与肝素的负离子(阴离子)结合,交换反应过程中形成的小分子盐类通过透析分离,截留所得大分子产物经过浓缩,浓缩后通过乙醇或丙酮沉淀的方法得到固体粉末成品;而后通过喷雾干燥得式(1)所示氨基葡萄糖肝素盐(成品)。
所述肝素盐与氨基葡萄糖盐类,混合或分别溶于水中,于膜内进行离子交换,氨基葡萄糖通过正离子(阳离子)与肝素的负离子(阴离子)结合,交换反应过程中形成的小分子盐类通过膜分离,截留所得大分子产物经过浓缩,浓缩后通过乙醇或丙酮沉淀的方法得到固体粉末成品;而后通过喷雾干燥得式(1)所示氨基葡萄糖肝素盐(成品)。
所述肝素盐与氨基葡萄糖盐类,混合或分别溶于水中,于离子交换柱内,氨基葡萄糖通过正离子(阳离子)与肝素的负离子(阴离子)结合,交换反应过程中形成的小分子盐类通过交换柱分离,截留所得大分子产物经过浓缩,浓缩后通过乙醇或丙酮沉淀的方法得到固体粉末成品;而后通过喷雾干燥得式(1)所示氨基葡萄糖肝素盐(成品)。
所述肝素盐与氨基葡萄糖盐类,混合或分别溶于水中,进行离子交换反应氨基葡萄糖通过正离子(阳离子)与肝素的负离子(阴离子)结合,向体系内加入醇,大分子通过加入的醇形成沉淀,小分子盐类溶于水中,而后过滤分离,喷雾干燥得式(1)所示氨基葡萄糖肝素盐(成品)。
一种氨基葡萄糖肝素盐的应用,所述式(1)所示氨基葡萄糖肝素盐在制备抗凝血类药物或功能食品中的应用。
所述药物或食品制成胶囊、片剂、散剂、颗粒剂或注射的剂型。
本发明所具有的优点:
本发明氨基葡萄糖肝素盐通过肝素分子上的羧基阴离子与硫酸根阴离子,与氨基葡萄糖阳离子有机结合,得到纯度更高的,无盐或少盐的、阴阳离子都是有机物的氨基葡萄糖肝素盐(或称为肝素氨基葡萄糖盐);具体为:
(1)氨基葡萄糖肝素盐把氨基葡萄糖与肝素通过离子键结合在一起,无盐或少盐,纯度可达90%以上,应用前景更广阔;
(2)氨基葡萄糖肝素盐可以满足人群更广,避免了钠离子、钙离子、氯离子、硫酸根离子、磷酸根等基团的副作用。
(3)氨基葡萄糖肝素盐增强了肝素的抗凝血作用。
附图说明
图1为氨基葡萄糖盐酸盐的核磁氢谱,其中,5.44和4.94ppm处为氨基葡萄糖分子糖环上1位平伏键和直立键的氢峰,3.91-3.30ppm化学位移范围内的峰为糖环上3,4,5,6位上的氢,3.00ppm处为2位氢峰。
图2为肝素钠的核磁氢谱,其中,5.41-4.82ppm处为葡萄糖胺、L-艾杜糖醛苷、N-乙酰葡萄糖胺和D-葡萄糖醛酸分子糖环上1位异头碳上氢的峰,4.40-3.36ppm化学位移范围内为葡萄糖胺、L-艾杜糖醛苷、N-乙酰葡萄糖胺和D-葡萄糖醛酸环上2,3,4,5位以及N-乙酰葡萄糖胺六员环上6位的氢峰,2.05ppm处为N-乙酰葡萄糖胺分子的乙酰基上甲基氢的峰。
图3为本发明实施例提的氨基葡萄糖肝素盐的合成路线图。
图4为本发明实施例提的氨基葡萄糖肝素盐的核磁氢谱,其中,5.44和4.94ppm处以及3.93-3.00ppm处尖锐峰为氨基葡萄糖糖环上1位和2-6位的氢峰。5.43-4.90ppm处为萄糖胺、L-艾杜糖醛苷、N-乙酰葡萄糖胺和D-葡萄糖醛酸分子中1位氢峰,4.39-3.99ppm处较宽的峰为葡萄糖胺、L-艾杜糖醛苷、N-乙酰葡萄糖胺和D-葡萄糖醛酸环上2,3,4,5位以及N-乙酰葡萄糖胺六员环上6位的氢峰,2.03ppm处为N-乙酰葡萄糖胺分子的乙酰基上甲基氢的峰。氨基葡萄糖肝素盐的氢谱中,氨基葡萄糖以及肝素的氢谱峰都存在,因此可以证明氨基葡萄糖肝素盐制备成功。
具体实施方式
以下实施例是对本发明的进一步说明,但本发明不局限于本实施方式中的制备方法和用途。
实施例1
称取5g分子量为80000的肝素(参见图2)与1g氨基葡萄糖盐酸盐(参见图1),溶解于水中,在截留分子量为500Da的透析袋中透析2天,旋蒸浓缩,冷冻干燥,得到氨基葡萄糖肝素盐(参见图3)。
实施例2
与实施例1不同之处在于:
称取2g分子量为10000的肝素与3g氨基葡萄糖盐酸盐,溶解于水中,在截留分子量为200Da的透析袋中透析3天,旋蒸浓缩,乙醇沉淀,抽滤,60摄氏度下烘干8小时,得到氨基葡萄糖肝素盐(参见图3)。
实施例3
与实施例1不同之处在于:
称取3g分子量为2000的肝素与2g氨基葡萄糖盐酸盐,溶解于水中,使用离子交换的方法,经阳离子交换器除去金属离子,再进入阴离子交换器除去阴离子,得到氨基葡萄糖肝素盐溶液,喷雾干燥,得到氨基葡萄糖肝素盐(参见图3)。
实施例4
与实施例1不同之处在于:
称取1g分子量为500的肝素与5g氨基葡萄糖盐酸盐,溶解于水中,使用电渗析的方法,采用电渗析脱盐设备,在电场作用下,经阴阳离子交换膜除去小分子盐,得到氨基葡萄糖肝素盐溶液,喷雾干燥,得到氨基葡萄糖肝素盐(参见图3)。
应用例1
活化部分凝血活酶时间(APTT)测定
待测血浆0.05mL,置于37℃下预温,分别加入37℃预温的肝素钠或上述实施例获得的氨基葡萄糖肝素盐样品水溶液0.05mL预温60s,接着加入APTT试剂盒悬液0.05mL,混匀,37℃孵育3min,加入37℃预温的0.025M的CaCl2溶液0.05mL,记录凝固时间。每个样品平行测定不少于3次,以生理盐水作阴性对照。
应用例2
凝血酶原时间(PT)测定
待测血浆0.05mL与肝素钠或上述实施例获得的氨基葡萄糖肝素盐样品水溶液0.05mL混匀,37℃预温3min,加入37℃预温的凝血酶原试剂(预温至少10min,但不多于30min;市购)0.1mL,混匀,记录凝固时间。每个样品平行测定不少于3次,以生理盐水作阴性对照。
应用例3
凝血酶时间(TT)测定
待测血浆0.1mL与肝素钠或上述实施例获得的氨基葡萄糖肝素盐样品溶液0.05mL混匀,37℃孵育3min,加入37℃预温的凝血酶试剂0.1mL,混匀,记录凝固时间。每个样品平行测定不少于3次,以生理盐水作阴性对照。
结果显示,肝素钠和氨基葡萄糖肝素盐的活化部分凝血活酶时间、凝血酶原时间以及凝血酶时间与水相比,显著增加。同时,在同浓度下,与肝素钠相比,氨基葡萄糖盐酸盐与肝素钠离子交换后得到的氨基葡萄糖肝素盐的活化部分凝血活酶时间、凝血酶原时间以及凝血酶时间变长,即氨基葡萄糖肝素盐的抗凝血活性比肝素钠的活性更强。而且,氨基葡萄糖盐酸盐与肝素钠离子交换后,使得肝素分子中的钠离子含量很低,副作用更小,进而可见氨基葡萄糖肝素盐在抗凝血活性方面具有巨大的应用潜力和价值。
Claims (3)
2.一种权利要求1所述的氨基葡萄糖肝素盐的应用,其特征在于:所述式(1)所示氨基葡萄糖肝素盐在制备抗凝血类药物或功能食品中的应用。
3.按权利要求2所述的氨基葡萄糖肝素盐的应用,其特征在于:所述药物或食品制成胶囊、片剂、散剂、颗粒剂或注射的剂型。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201911242820.0A CN110878129B (zh) | 2019-12-06 | 2019-12-06 | 一种氨基葡萄糖肝素盐及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201911242820.0A CN110878129B (zh) | 2019-12-06 | 2019-12-06 | 一种氨基葡萄糖肝素盐及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN110878129A CN110878129A (zh) | 2020-03-13 |
CN110878129B true CN110878129B (zh) | 2022-02-01 |
Family
ID=69729935
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201911242820.0A Active CN110878129B (zh) | 2019-12-06 | 2019-12-06 | 一种氨基葡萄糖肝素盐及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110878129B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114805638B (zh) * | 2021-01-22 | 2024-06-21 | 烟台东诚药业集团股份有限公司 | 一种肝素钠粗品纯化的方法 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES425303A1 (es) * | 1973-04-13 | 1976-12-16 | Choay Sa | Un procedimiento de fabricacion de sales de heparina sim- ples. |
EP1375524A1 (en) * | 2002-06-20 | 2004-01-02 | CHEMI S.p.A. | Process for the preparation of esters of heparin |
CN1580080A (zh) * | 2004-05-20 | 2005-02-16 | 汕头市金丰医疗器械科技有限公司 | 一种肝素化合物及其制备方法和应用 |
CN104829750A (zh) * | 2015-05-26 | 2015-08-12 | 苏州鸿洋医药科技有限公司 | 肝素锂的精制工艺 |
CN108276458A (zh) * | 2018-03-07 | 2018-07-13 | 中国科学院烟台海岸带研究所 | 一种氨基葡萄糖绿原酸盐及其制备方法和应用 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006089167A1 (en) * | 2005-02-18 | 2006-08-24 | Cartilix, Inc. | Glucosamine materials |
-
2019
- 2019-12-06 CN CN201911242820.0A patent/CN110878129B/zh active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES425303A1 (es) * | 1973-04-13 | 1976-12-16 | Choay Sa | Un procedimiento de fabricacion de sales de heparina sim- ples. |
EP1375524A1 (en) * | 2002-06-20 | 2004-01-02 | CHEMI S.p.A. | Process for the preparation of esters of heparin |
CN1580080A (zh) * | 2004-05-20 | 2005-02-16 | 汕头市金丰医疗器械科技有限公司 | 一种肝素化合物及其制备方法和应用 |
CN104829750A (zh) * | 2015-05-26 | 2015-08-12 | 苏州鸿洋医药科技有限公司 | 肝素锂的精制工艺 |
CN108276458A (zh) * | 2018-03-07 | 2018-07-13 | 中国科学院烟台海岸带研究所 | 一种氨基葡萄糖绿原酸盐及其制备方法和应用 |
Non-Patent Citations (3)
Title |
---|
RELATIONSHIP OF MOLECULAR-WEIGHT, AND SULFATE CONTENT AND DISTRIBUTION TOANTICOAGULANT ACTIVITY OF HEPARIN PREPARATIONS;JOSEPH A. CIFONELLI;《CARBOHYDRATE RESEARCH》;20010308;第37卷(第1期);第145-154页 * |
壳聚糖氨基酸衍生物的制备及其抗凝血性能研究;张世才;《中国优秀硕士学位论文全文数据库 工程科技I辑》;20140915(第09期);B016-330 * |
肝素类抗凝药物优化设计研究进展;桑青等;《中国生化药物杂志》;20120420;第33卷(第2期);第188-191页 * |
Also Published As
Publication number | Publication date |
---|---|
CN110878129A (zh) | 2020-03-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPS62209101A (ja) | エキナセアプルプレアまたはエキナセアアングステイフオリアの細胞培養物からの免疫刺激作用性ポリサツカライド、その製造方法及びこれを含む製剤 | |
CN1379781A (zh) | 新的低聚糖、其制备方法及其药物组合物 | |
JP2020507666A (ja) | オゾンを用いた多糖類の分解方法 | |
CN110878129B (zh) | 一种氨基葡萄糖肝素盐及其应用 | |
JP2006291028A (ja) | 低分子ヘパリンまたはその塩、ならびにその製造方法 | |
CN108503724A (zh) | 蛹虫草培养基多糖及其分离纯化方法和应用 | |
CN110950976A (zh) | 一种氨基葡萄糖透明质酸盐及应用 | |
CN116003645A (zh) | 一种泡叶藻岩藻多糖及其制备和纯化方法 | |
CN104004109A (zh) | 海洋硫酸酯化糖胺聚糖se-3及其制备方法 | |
CN107936135B (zh) | 一种高纯度甘露次聚糖的制备方法及其应用 | |
CN112661797A (zh) | 一种低水分活度氨基葡萄糖盐酸盐及其制备方法与应用 | |
CN108096273B (zh) | 硫酸化葡萄糖醛酸寡糖的应用 | |
CN104262508A (zh) | 一种汀肝素钠制备工艺 | |
CN102585034B (zh) | 果胶磺化的方法 | |
JPS6121102A (ja) | キトサンオリゴ糖の製造法 | |
CN111635464A (zh) | 一种5-氨基酮戊酸葡聚糖酯的制备方法 | |
CN112076211A (zh) | 糖胺聚糖组合物及其制备方法与应用 | |
CN110872361A (zh) | 一种氨基葡萄糖硫酸软骨素盐和制备方法及应用 | |
CN106084085B (zh) | 一种低分子量褐藻多糖硫酸酯的制备方法及应用 | |
CN115043956B (zh) | 一种接骨木多糖及其多糖组合物与应用 | |
JP2714663B2 (ja) | 腸内有益菌増殖促進剤 | |
CN113429443B (zh) | 一种双唾液酸-甘露寡糖复合物及其合成方法 | |
CN114560962B (zh) | 具有抗肿瘤活性海洋低聚寡糖的制备方法、海洋低聚寡糖及其应用 | |
CN102603923B (zh) | 一种肝素钙化合物及其制法 | |
JPH01313503A (ja) | ヒアルロン酸の精製法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |